Wuhan Healthgen Biotechnology Corp. (SHA:688765)

China flag China · Delayed Price · Currency is CNY
53.33
-7.11 (-11.76%)
At close: Apr 28, 2026
Market Cap19.07B
Revenue (ttm)23.39M -3.6%
Net Income-160.81M
EPS-0.59
Shares Out357.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,462,674
Average Volume1,393,332
Open59.35
Previous Close60.44
Day's Range51.88 - 59.35
52-Week Range51.88 - 132.03
Betan/a
RSI23.25
Earnings DateApr 17, 2026

About SHA:688765

Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial growth factor, recombinant human keratinocyte growth factor, recombinant human... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2006
Employees 215
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688765
Full Company Profile

Financial Performance

In 2024, SHA:688765's revenue was 25.22 million, an increase of 3.92% compared to the previous year's 24.26 million. Losses were -151.37 million, -19.04% less than in 2023.

Financial Statements